Diflunisal
An NSAID derived from salicylic acid, used to treat mild to moderate pain including that from osteoarthritis. It is metabolized differently from aspirin and does not produce the same level of antiplatelet effects. Its half-life is longer than aspirin, allowing twice-daily dosing.
Moleküler Ağırlık
250,2000 g/mol
LogP
4,40
TPSA
57,50 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
2D Yapı
Cite this structure
Embed this structure
SMILES
O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
InChI
InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
Molecular Formula
C13H8F2O3
HBD / HBA
2 / 5
Döndürülebilir Bağlar
2
Ağır Atomlar
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
An NSAID derived from salicylic acid, used to treat mild to moderate pain including that from osteoarthritis. It is metabolized differently from aspirin and does not produce the same level of antiplatelet effects. Its half-life is longer than aspirin, allowing twice-daily dosing.
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.
Yes, Diflunisal is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL898. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3059. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="diflunisal"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/diflunisal/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/diflunisal/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/diflunisal/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="diflunisal"></drugfyi-drug>